IGC Pharma (NYSE American: IGC), a visionary clinical-stage pharmaceutical company, has achieved a significant milestone; the company has received notice from the European Patent Office that the patent for its proprietary “Cannabinoid Composition and Method for Treating Pain” has been granted. According to the announcement, the patent covers IGC Pharma’s pioneering method for treating pain in humans, which uses a topical cream base infused with a unique blend of cannabinoids, including tetrahydrocannabinol (THC) and cannabidiol (CBD). Designed for transdermal absorption, the topical cream interacts with the peripheral nervous and immune systems to deliver effective pain relief without psychotropic or adverse side effects. The market for an effective pain-relief treatment is significant. In America alone, more than 56 million individuals struggle with debilitating arthritis, while 10% to 30% of total joint arthroplasty patients experience persistent pain. IGC Pharma is at the forefront of innovation, dedicated to enhancing the quality of life and well-being of those in pain.
“IGC Pharma is committed to advancing pain-relief therapies rooted in decades of rigorous scientific research,” said IGC Pharma CEO Ram Mukunda in the press release. “We aspire to redefine the standard for pain management, providing healthier alternatives to traditional medications. Our portfolio now boasts an impressive 35 patent filings in various countries, including the U.S. and Canada. We are proud to have achieved this milestone as we work to expand our roster of pain management formulations, and we will continue to innovate and develop new solutions to address this issue. I believe that our innovative approach to pain relief has the potential to disrupt the industry, providing investors with a unique chance to be part of a transformative journey.”
To view the full press release, visit https://ibn.fm/17Ne3
About IGC Pharma Inc.
IGC Pharma (dba IGC) develops advanced cannabinoid-based formulations for treating diseases and conditions, including but not limited to Alzheimer’s disease, period cramps (dysmenorrhea), premenstrual syndrome (“PMS”) and chronic pain. IGC has two investigational drug assets — IGC-AD1 and TGR-63 — targeting Alzheimer’s disease, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (“THC”)-based formulation that is currently in a 146-person phase 2 clinical trial for agitation in dementia due to Alzheimer’s. For more information, visit the company’s website at www.IGCInc.us.
NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
